Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12966092
Gardner OS, et al. (2003) Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 278, 46261-9 12966092
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y870-p - EGFR (rat)
Modsite: LGAEEKEyHAEGGKV SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y869‑p, EGFR iso2 (human): , EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PP2 EGF no effect upon treatment-induced increase
PP3 EGF no effect upon treatment-induced increase
NAC EGF no effect upon treatment-induced increase
nafenopin increase
PP2 nafenopin inhibit treatment-induced increase
PP3 nafenopin no effect upon treatment-induced increase
NAC nafenopin inhibit treatment-induced increase
ciglitazone increase
PP2 ciglitazone inhibit treatment-induced increase
PP3 ciglitazone no effect upon treatment-induced increase
NAC ciglitazone inhibit treatment-induced increase
troglitazone no change compared to control

Y1091-p - EGFR (rat)
Modsite: TFLPVPEyINQSVPK SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1092‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin increase
ciglitazone increase
troglitazone increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin HRas (human) increase
gefitinib nafenopin HRas (human) inhibit treatment-induced increase
PD153035 nafenopin HRas (human) inhibit treatment-induced increase
U0126 nafenopin HRas (human) inhibit treatment-induced increase
PP2 nafenopin HRas (human) inhibit treatment-induced increase
PP3 nafenopin HRas (human) no effect upon treatment-induced increase
NAC nafenopin HRas (human) inhibit treatment-induced increase
ciglitazone HRas (human) increase
gefitinib ciglitazone HRas (human) inhibit treatment-induced increase
PD153035 ciglitazone HRas (human) inhibit treatment-induced increase
U0126 ciglitazone HRas (human) inhibit treatment-induced increase
PP2 ciglitazone HRas (human) inhibit treatment-induced increase
PP3 ciglitazone HRas (human) no effect upon treatment-induced increase
NAC ciglitazone HRas (human) inhibit treatment-induced increase
troglitazone increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin HRas (human) increase
gefitinib nafenopin HRas (human) inhibit treatment-induced increase
PD153035 nafenopin HRas (human) inhibit treatment-induced increase
U0126 nafenopin HRas (human) inhibit treatment-induced increase
PP2 nafenopin HRas (human) inhibit treatment-induced increase
PP3 nafenopin HRas (human) no effect upon treatment-induced increase
NAC nafenopin HRas (human) inhibit treatment-induced increase
ciglitazone HRas (human) increase
gefitinib ciglitazone HRas (human) inhibit treatment-induced increase
PD153035 ciglitazone HRas (human) inhibit treatment-induced increase
U0126 ciglitazone HRas (human) inhibit treatment-induced increase
PP2 ciglitazone HRas (human) inhibit treatment-induced increase
PP3 ciglitazone HRas (human) no effect upon treatment-induced increase
NAC ciglitazone HRas (human) inhibit treatment-induced increase
troglitazone increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin HRas (human) increase
gefitinib nafenopin HRas (human) inhibit treatment-induced increase
PD153035 nafenopin HRas (human) inhibit treatment-induced increase
U0126 nafenopin HRas (human) inhibit treatment-induced increase
PP2 nafenopin HRas (human) inhibit treatment-induced increase
PP3 nafenopin HRas (human) no effect upon treatment-induced increase
NAC nafenopin HRas (human) inhibit treatment-induced increase
ciglitazone HRas (human) increase
gefitinib ciglitazone HRas (human) inhibit treatment-induced increase
PD153035 ciglitazone HRas (human) inhibit treatment-induced increase
U0126 ciglitazone HRas (human) inhibit treatment-induced increase
PP2 ciglitazone HRas (human) inhibit treatment-induced increase
PP3 ciglitazone HRas (human) no effect upon treatment-induced increase
NAC ciglitazone HRas (human) inhibit treatment-induced increase
troglitazone increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin HRas (human) increase
gefitinib nafenopin HRas (human) inhibit treatment-induced increase
PD153035 nafenopin HRas (human) inhibit treatment-induced increase
U0126 nafenopin HRas (human) inhibit treatment-induced increase
PP2 nafenopin HRas (human) inhibit treatment-induced increase
PP3 nafenopin HRas (human) no effect upon treatment-induced increase
NAC nafenopin HRas (human) inhibit treatment-induced increase
ciglitazone HRas (human) increase
gefitinib ciglitazone HRas (human) inhibit treatment-induced increase
PD153035 ciglitazone HRas (human) inhibit treatment-induced increase
U0126 ciglitazone HRas (human) inhibit treatment-induced increase
PP2 ciglitazone HRas (human) inhibit treatment-induced increase
PP3 ciglitazone HRas (human) no effect upon treatment-induced increase
NAC ciglitazone HRas (human) inhibit treatment-induced increase
troglitazone increase

T180-p - P38A (rat)
Modsite: RHTDDEMtGyVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin increase
gefitinib nafenopin no effect upon treatment-induced increase
PD153035 nafenopin no effect upon treatment-induced increase
U0126 nafenopin no effect upon treatment-induced increase
PP2 nafenopin no effect upon treatment-induced increase
NAC nafenopin no effect upon treatment-induced increase
ciglitazone increase
gefitinib ciglitazone no effect upon treatment-induced increase
PD153035 ciglitazone no effect upon treatment-induced increase
U0126 ciglitazone no effect upon treatment-induced increase
PP2 ciglitazone no effect upon treatment-induced increase
PP3 ciglitazone no effect upon treatment-induced increase
NAC ciglitazone no effect upon treatment-induced increase
troglitazone increase

Y182-p - P38A (rat)
Modsite: TDDEMtGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin increase
gefitinib nafenopin no effect upon treatment-induced increase
PD153035 nafenopin no effect upon treatment-induced increase
U0126 nafenopin no effect upon treatment-induced increase
PP2 nafenopin no effect upon treatment-induced increase
NAC nafenopin no effect upon treatment-induced increase
ciglitazone increase
gefitinib ciglitazone no effect upon treatment-induced increase
PD153035 ciglitazone no effect upon treatment-induced increase
U0126 ciglitazone no effect upon treatment-induced increase
PP2 ciglitazone no effect upon treatment-induced increase
PP3 ciglitazone no effect upon treatment-induced increase
NAC ciglitazone no effect upon treatment-induced increase
troglitazone increase

Y419-p - Src (rat)
Modsite: RLIEDNEyTARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  GN4 (epithelial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nafenopin increase
PP2 nafenopin inhibit treatment-induced increase
PP3 nafenopin no effect upon treatment-induced increase
ciglitazone increase
PP2 ciglitazone inhibit treatment-induced increase
PP3 ciglitazone no effect upon treatment-induced increase